28544601|t|The impact of noninvasive follicular thyroid neoplasm with papillary-like nuclear features on the performance of the Afirma gene expression classifier
28544601|a|A recent revision in thyroid tumor nomenclature has resulted in a change from a malignant diagnosis (noninvasive follicular variant of papillary thyroid carcinoma) to one that is nonmalignant (noninvasive follicular thyroid neoplasm with papillary-like nuclear features [NIFTP]). The objective of the current study was to evaluate the impact of this change on the performance of the Afirma gene expression classifier (GEC). The authors retrospectively analyzed consecutive thyroid fine-needle aspiration specimens with indeterminate diagnoses on which GEC was performed. Surgical pathology material was reviewed with the reclassification of nodules into NIFTP. GEC testing was performed on 384 fine-needle aspiration specimens diagnosed as atypia of undetermined significance (AUS) (304 cases) and suspicious for a follicular neoplasm (SFN) (80 cases) and yielded a suspicious result in 152 of the AUS cases (50%) and 50 of the SFN cases (63%). Thyroidectomy was performed on 177 patients. After reclassifying NIFTP, the positive predictive value of GEC decreased from 42% (95% confidence interval [95% CI], 39%-45%) to 24% (95% CI, 22%-26%) in the AUS group and from 23% (95% CI, 19%-27%) to 13% (95% CI, 9%-18%) in the SFN group. Total thyroidectomy was performed more frequently than a partial thyroidectomy in patients with AUS with a suspicious GEC result compared with pre-GEC controls (68% vs 49%; P = .037). Reclassification of NIFTP significantly decreases the positive predictive value of GEC in indeterminate thyroid nodules. Nevertheless, the majority of patients with indeterminate thyroid nodules with a suspicious GEC result in the study institution have undergone total thyroidectomy. This finding raises concerns over reliance on a suspicious GEC result by clinicians to justify total thyroidectomy. Cancer Cytopathol 2017. Â© 2017 American Cancer Society.
28544601	4	10	impact	T080	C4049986
28544601	14	90	noninvasive follicular thyroid neoplasm with papillary-like nuclear features	T191	C4287590
28544601	98	109	performance	T052	C1882330
28544601	117	150	Afirma gene expression classifier	T062	C0242481
28544601	172	185	thyroid tumor	T191	C0040136
28544601	186	198	nomenclature	T170	C0600281
28544601	231	240	malignant	T080	C0205282
28544601	241	250	diagnosis	T033	C0011900
28544601	252	313	noninvasive follicular variant of papillary thyroid carcinoma	T191	C0238463
28544601	330	342	nonmalignant	T080	C1518371
28544601	344	420	noninvasive follicular thyroid neoplasm with papillary-like nuclear features	T191	C4287590
28544601	422	427	NIFTP	T191	C4287590
28544601	460	465	study	T062	C2603343
28544601	486	492	impact	T080	C4049986
28544601	515	526	performance	T052	C1882330
28544601	534	567	Afirma gene expression classifier	T062	C0242481
28544601	569	572	GEC	T062	C0242481
28544601	587	611	retrospectively analyzed	T062	C0936012
28544601	624	654	thyroid fine-needle aspiration	T060	C0193787
28544601	655	664	specimens	T167	C0370003
28544601	684	693	diagnoses	T060	C0011911
28544601	703	706	GEC	T062	C0242481
28544601	722	749	Surgical pathology material	T167	C0520510
28544601	772	788	reclassification	T185	C0008902
28544601	792	799	nodules	T020	C0028259
28544601	805	810	NIFTP	T191	C4287590
28544601	812	815	GEC	T062	C0242481
28544601	845	867	fine-needle aspiration	T060	C0193787
28544601	868	877	specimens	T167	C0370003
28544601	878	887	diagnosed	T033	C0011900
28544601	891	926	atypia of undetermined significance	T033	C0243095
28544601	928	931	AUS	T033	C0243095
28544601	938	943	cases	T169	C0868928
28544601	966	985	follicular neoplasm	T191	C0474808
28544601	987	990	SFN	T191	C0474808
28544601	996	1001	cases	T169	C0868928
28544601	1049	1052	AUS	T033	C0243095
28544601	1053	1058	cases	T169	C0868928
28544601	1079	1082	SFN	T191	C0474808
28544601	1083	1088	cases	T169	C0868928
28544601	1096	1109	Thyroidectomy	T061	C0040145
28544601	1131	1139	patients	T101	C0030705
28544601	1147	1160	reclassifying	T185	C0008902
28544601	1161	1166	NIFTP	T191	C4287590
28544601	1181	1197	predictive value	T080	C1514307
28544601	1201	1204	GEC	T062	C0242481
28544601	1205	1214	decreased	T081	C0205216
28544601	1229	1248	confidence interval	T081	C0009667
28544601	1254	1256	CI	T081	C0009667
28544601	1280	1282	CI	T081	C0009667
28544601	1300	1303	AUS	T033	C0243095
28544601	1304	1309	group	T101	C0030705
28544601	1328	1330	CI	T081	C0009667
28544601	1353	1355	CI	T081	C0009667
28544601	1372	1375	SFN	T191	C0474808
28544601	1376	1381	group	T101	C0030705
28544601	1389	1402	thyroidectomy	T061	C0040145
28544601	1448	1461	thyroidectomy	T061	C0040145
28544601	1465	1473	patients	T101	C0030705
28544601	1479	1482	AUS	T033	C0243095
28544601	1501	1504	GEC	T062	C0242481
28544601	1526	1542	pre-GEC controls	T096	C0009932
28544601	1567	1583	Reclassification	T185	C0008902
28544601	1587	1592	NIFTP	T191	C4287590
28544601	1607	1616	decreases	T081	C0547047
28544601	1630	1646	predictive value	T080	C1514307
28544601	1650	1653	GEC	T062	C0242481
28544601	1671	1678	thyroid	T023	C0040132
28544601	1679	1686	nodules	T020	C0028259
28544601	1718	1726	patients	T101	C0030705
28544601	1746	1753	thyroid	T023	C0040132
28544601	1754	1761	nodules	T020	C0028259
28544601	1780	1783	GEC	T062	C0242481
28544601	1798	1803	study	T062	C2603343
28544601	1804	1815	institution	T093	C2607850
28544601	1837	1850	thyroidectomy	T061	C0040145
28544601	1872	1880	concerns	T078	C2699424
28544601	1911	1914	GEC	T062	C0242481
28544601	1925	1935	clinicians	T097	C0871685
28544601	1953	1966	thyroidectomy	T061	C0040145